medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2020, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (1)

Prevalence of Hepatitis B virus markers in Cuban blood donors

Montalvo VMC, Rodriguez LLÁ, López HD, Bello CM, Marrero SBH, Sánchez AML

Language: Spanish
References: 28
Page: 1-14
PDF size: 653.73 Kb.


ABSTRACT

Introduction: The incidence of hepatitis B in Cuba has decreased significantly since incorporation of Cuban vaccine Heberbiovac HB.
Objective: To determine the prevalence of hepatitis B virus markers in blood donors from three provinces and the persistence of antibodies against surface antigen of this virus in blood donors born after introduction of Cuban vaccine in the National Immunization Program.
Methods: The design of a prevalence study was applied. We included 433 donors who attended the blood banks of the provinces of Havana, Villa Clara and Santiago de Cuba, between January and December 2018.The HBsAg, anti-HBc and anti-HBs markers were detected; the latter was detected in donors aged 18-26 years. The real-time analysis of C-reactive protein (CRP) was performed to identify viral replication in individuals positive to HBsAg-positive and to anti-HBc.
Results: The prevalence of HBsAg and anti-HBc was 1.15% (5/433) and 7.85% (38/433), respectively. In individuals born after introduction of the vaccine, the prevalence of HBsAg and anti-HBc was 0% and 0.95%, respectively. 36.19% (38/105) of these donors had protective levels of anti-HBs (≥10UI/L). Viral DNA was detected in a donor positive to HBsAg and to anti-HBc. Hidden infection with the hepatitis B virus was not identified.
Conclusions: The prevalence of HBsAg is low among Cuban blood donors, with a tendency to be null in donors born after application of Cuban vaccine Heberbiovac HB.


REFERENCES

  1. Sugiyama A, Ohisa M, Nagashima S, Yamamoto C, Chuon C, Fujii T, et al. Reduced prevalence of hepatitis B surface antigen positivity among pregnant women born after the national implementation of immunoprophylaxis for babies born to hepatitis B virus-carrier mothers in Japan. Hepatol Res. 2017;47(12):1329-34. doi: 10.1111/hepr.12943

  2. Organización Mundial de la Salud. Necesidad de actuar urgentemente a nivel mundial contra las hepatitis. [acceso 22/02/2019]. Disponible en: https://www.who.int/es/news-room/detail/21-04-2017-new-hepatitis-data-highlight-need-for-urgent-global-response

  3. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2017. La Habana: Ministerio de Salud Pública; 2017. [acceso 25/03/2019]. Disponible en: http://http://files.sld.cu/dne/files/2018/04/Anuario-Electronico-Espa%C3%B1ol-2017-ed-2018.pdf

  4. López Ambrón L, Egües Torres LI, Pérez Carreras A, Galindo Santana BM, Galindo Sardiña MA, Resik Aguirre S, et al. Experiencia cubana en inmunización, 1962-2016. Rev Panam Salud Pub. 2018;42:e34. doi: 10.26633/RPSP.2018.34

  5. Betancourt AA, Delgado CA, Estevez ZC, Martinez JC, Rios GV, Aureoles-Rosello SR, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. International journal of infectious diseases. Int J Infect Dis. 2007;11(5):394-401. doi: 10.1016/j.ijid.2006.09.010

  6. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2016. La Habana: Ministerio de Salud Pública; 2016 [acceso 06/03/2018]. Disponible en: http://files.sld.cu/dne/files/2018/04/Anuario-Electronico-Espa%C3%B1ol-2017-ed-2018.pdf

  7. Castellano MI, Dorta Z, Conde-EduardoP, Galban E, Arus E, Martínez Y. Current Condition of Chronic Hepatitis B Virus Infection in Cuban Adults. Curr Ther Res Clin Exp. 2017;85:15-9. doi: 10.1016/j.curtheres.2017.04.007

  8. Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune response to vaccination. Vaccine. 2015;33(36):4422-9.doi:10.1016/j.vaccine.2015.06.101.

  9. O'Brien SF, Yi QL, Fan W, Scalia V, Goldman M, Fearon MA. Residual risk of HIV, HCV and HBV in Canada. Transfus Apher Sci. 2017;56(3):389-91. doi: 10.1016/j.transci.2017.03.010

  10. Dodd RY, Nguyen ML, Krysztof DE, Notari EP, Stramer SL. Blood donor testing for hepatitis B virus in the United States: is there a case for continuation of hepatitis B surface antigen detection? Transfusion. 2018;58(9):2166-70. doi: 10.1111/trf.14784

  11. Hofstraat SHI, Falla AM, Duffell EF, Hahne SJM, Amato-Gauci AJ, Veldhuijzen IK, et al. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol Infect. 2017;145(14):2873-85. doi: 10.1017/S0950268817001947

  12. Beltran-Duran M, Berrio-Perez M, Bermudez-Forero MI, Cortes-Buelvas AD, Molina-Guevara GC, Camacho-Rodriguez BA, et al. Serological Profiles of Hepatitis-B HBcAb-Positive Blood donors. Rev Salud Pub (Bogota). 2014;16(6):847-58. doi: 10.15446/rsap.v16n6.28848

  13. Sosa-Jurado F, Rosas-Murrieta N, Guzman-Flores B, Perez Zempoaltecalt C, Sanchez P, Ramirez RL, et al. Prevalence of Serologic Hepatitis B Markers in Blood Donors From Puebla, Mexico: The Association of Relatively High Levels of Anti-Core Antibodies With the Detection of Surface Antigen and Genomic DNA. Hepat Mon. 2016;16(6):e36942. doi: 10.1186/s12879-016-1834-2

  14. Organización Panamericana de la Salud. Suministro de sangre para transfusiones en los países de Latinoamérica y del Caribe, 2014 y 2015. Washington, D.C.: OPS; 2017 [acceso 23/08/2017]. Disponible en: http://iris.paho.org/xmlui/bitstream/handle/123456789/34082/9789275319581-spa.pdf?sequence=1&isAllowed=y

  15. Dionne-Odom J, Mbah R, Rembert NJ, Tancho S, Halle-Ekane GE, Enah C, et al. Hepatitis B, HIV, and Syphilis Seroprevalence in Pregnant Women and Blood Donors in Cameroon. Infect Dis Obstet Gynecol. 2016 [acceso 23/08/2017];4359401. doi: 10.1155/2016/4359401. Disponible en: https://www.hindawi.com/journals/idog/2016/4359401/

  16. Boushab BM, Mohamed Limame OCM, Fatim Zahra FM, Mamoudou S, Roseline Darnycka BM, Saliou SM. Estimation of seroprevalence of HIV, hepatitis B and C virus and syphilis among blood donors in the hospital of Aioun, Mauritania. Pan Afr Med J. 2017;28:118. doi: 10.3389/fmed.2018.00029

  17. Bello-CorredorM, Montalvo MC, Rodriguez L, Sariego S, Verdasquera D, Vincent M, et al. Occult hepatitis B in Cuban HIV patients. MEDICC review. 2011;13(2):32-7.

  18. Hussein N. Risk factors of hepatitis B virus infection among blood donors in Duhok city, Kurdistan Region, Iraq. Caspian J Intern Med. 2018;9(1):22-6. doi: 10.1371/journal.pone.0191970

  19. Moresco MN, Virgolino HA, de Morais MP, da Motta-Passos I, Gomes-Gouvea MS, de Assis LM, et al. Occult hepatitis B virus infection among blood donors from the Brazilian Amazon: implications for transfusion policy. Vox Sang. 2014;107(1):19-25.doi: 10.1111/vox.12125

  20. Delfino CM, Gentile EA, Castillo AI, Cuestas ML, Pataccini G, Canepa C, et al. Hepatitis B virus and hepatitis D virus in blood donors from Argentina: circulation of HBsAg and reverse transcriptase mutants. Arch Virol. 2014;159(5):1109-17.doi: 10.1007/s00705-013-1917-y

  21. Bello-Corredor M, Rodríguez LL, Argueta D, Montalvo-Villalba MC, Pedroso-Flaquet P, Sariego-Frómeta S, et al. Infección oculta por el virus de la hepatitis B en hijos de madres positivas al HBsAg. VacciMonitor. 2016;25(1):12-8

  22. Rios-Ocampo WA, Cortes-Mancera F, Olarte JC, Soto A, Navas MC. Occult hepatitis B virus infection among blood donors in Colombia. Virol J. 2014;201:11. doi: 10.1186/1756-0500-7-873

  23. Ogunfemi MK, Olawumi HO, Olokoba AB, Kagu MB, Biliaminu SA, Durowade KA, et al. Prevalence of antibody to hepatitis B core antigen among hepatitis B surface antigen-negative blood donors in Ilorin, Nigeria: A cross-sectional study. Malawi Med J. 2017;29(1):32-6. doi: 10.7860/jcdr/2017/25137.9649

  24. Mahmoud AI, Elsherbiny NM, Afifi NA, Ahmed BM, Yasin AS. Occult Hepatitis B Infection Among Blood Donors in Al Azhar University Hospital, Upper Egypt: The Current Status After 25 years of Vaccine Introduction. Egypt J Immunol. 2018;25(1):45-56.

  25. Candotti D, Laperche S. Hepatitis B Virus Blood Screening: Need for Reappraisal of Blood Safety Measures? Front Med (Lausanne). 2018;5:29. doi: 10.1186/s13104-018-3276-y

  26. Hernandez-Bernal F, Aguilar-Betancourt A, Aljovin V, Arias G, Valenzuela C, de Alejo KP, et al. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults. Hum Vaccines. 2011;7(10):1026-36. doi: 10.4161/hv.7.10.15989

  27. Wang Z, Zeng J, Li T, Zheng X, Xu X, Ye X, et al. Prevalence of hepatitis B surface antigen (HBsAg) in a blood donor population born prior to and after implementation of universal HBV vaccination in Shenzhen, China. BMC InfectDis. 2016;16:498. doi: 10.1186/s12879-016-1834-2

  28. Hsu SH, Chih AH, Lee YC, Huang KC, Jan CF. Higher disappearance rate of anti-HBs in Taiwanese freshers neonatally vaccinated with recombinant yeast hepatitis B vaccine. Liver Int. 2017;37(12):1780-7. doi: 10.1111/liv.13437




2020     |     www.medigraphic.com